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Safe and Effective Method in Patients with Complicated Injuries
R. Clement Darling III, Saum Rahimi, Manish Mehta, John B. Taggert,
Sean P. Roddy, Yaron Sternbach, Kathleen J. Ozsvath, Paul B Kreienberg,
Philip S.K. Paty, and Dhiraj M. Shah, From Albany Medical College, Al-
bany, NY
Objectives: Historically thoracic aortic rupture secondary to trauma
was treated with cardiopulmonary bypass and open surgery. With the advent
of endovascular grafting, physicians have the ability to reconstruct the
thoracic aortic transection using a less invasive technique. In this study, we
examine our experience with stent graft repair of thoracic transections
secondary to trauma.
Methods: Records of patients treated at a level 1 trauma center were
reviewed from 2006-2008. Those patients who had an aortic transection
identified were evaluated for in-hospital mortality and morbidity as well as
concurrent injuries. Demographics, procedural details, and outcomes were
analyzed.
Results: During a 3-year period, 19 thoracic aortic transections sec-
ondary to trauma were identified in patients with a mean age of 44 years
(range, 19-80 years). Primary technical success was 100%. None of the
patients required explant or open repair. In-hospital mortality was 1 of 19
(5%); 18 patients had multiple trauma, including long-bone fractures. The
subclavian artery origin was covered by the stent graft in nine patients. The
mean estimated blood loss per procedure was 205 mL. No patient in this
series suffered postoperative paraplegia. Follow-up averaged 10 months
(range, 1-38 months). No late explantation or device failures have been
identified.
Conclusion: Vascular repair of traumatic thoracic aortic transections
can be performed safely, with a low mortality and morbidity, and should be
the procedure of choice for patients presenting with traumatic thoracic
aortic ruptures.
Trends and Outcomes of Endovascular and Open Treatment for Trau-
matic Thoracic Aortic Injury
Frederik H. Jonker,a Jeanine K. Giacovelli,b Bart E. Muhs,a and Jeffrey
Indes,a From the Yale University School of Medicine, New Havena; and the
Mount Sinai School of Medicine, New York,b New Haven, Conn; and New
York, NY
Objectives: Data supporting endovascular thoracic aortic repair
(TEVAR) to reduce morbidity and mortality for traumatic thoracic aortic
injury (TTAI) is limited to case series and meta-analyses. In this study, we
evaluated the trends and outcomes of open surgery and TEVAR for TTAI in
New York State.
Methods: All cases of TTAI in New York State between 2000 and
2006 were extracted from the New York Statewide Planning and Research
Cooperative System (SPARCS) database. A diagnosis by International
Classification of Diseases, 9th Revision, coding of TTAI was required for
inclusion.
Results: We identified 569 patients with TTAI, and 274 (48%) re-
ceived surgical repair. Open surgery was performed in 238 (87%) and
TEVAR in 36 (13%). Endovascular management was used during the last 2
years of the study and exceeded the number of open procedures in the last
year. The overall mortality rate for the 7-year period was 11.1% in the
TEVAR group and 18.1% in the open surgery group (odds ratio, 1.76; 95%
confidence interval, 0.59-5.25, P  .302). TEVAR appeared to lower the
incidence of respiratory (22.2% vs 38.7%, P  .056), cardiac (0% vs 5.9%,
P  .135), and postoperative bleeding (8.3% vs 26.1%, P  .020)
complications compared with patients undergoing open surgery. The
incidence of paraplegia did not differ significantly between the groups;
distal embolization was increased after TEVAR (11.1% vs 0%, P  .001)
and endoleak occurred in 11.1%. More patients undergoing TEVAR
were discharged home compared with those treated with open repair
(44.4% vs 28.6%, P  .054).
Conclusions: Recently, there has been a shift towards endovascular
management of patients with TTAI. This trend appears to result in improved
mortality, morbidity, and the frequency of discharge to home. However,
TEVAR may be associated with significant device-related complications.
Propensity Score Analysis Validates Findings of the VALOR Trial
(TEVAR For Degenerative Thoracic Aneurysms)
Virendra I. Patel,a Mark F. Conrad,a Christopher J. Kwolek,a Ronald M.
Fairman,b and Richard P. Cambria,a FromMassachusetts General Hospital,
a bBoston ; and the Hospital of the University of Pennsylvania, Philadelphia,
Boston, Mass; and Philadelphia, PaIntroduction: The VALOR trial reported superior outcomes of the
Talent thoracic endovascular aneurysm repair (TEVAR) compared with
surgery for descending thoracic aneurysms (JVS 2008;48:546-54). Data
from 195 prospective TEVAR patients were compared with 189 historical
surgical controls (OG) included into the trial after completion of TEVAR
enrollment. Such retrospective comparisons are biased by differences among
TEVAR vs OG. This applied study propensity score (PS) analysis, which
reduces bias by participant matching, to validate findings of the VALOR
trial.
Methods: Logistic regression generated a PS (range, 0-1) to identify
characteristics more likely in TEVAR. The PS estimated the probability a
patient would undergo TEVAR (eg, a PS of 0.99  a 99% chance a patient
belongs to TEVAR). PS was used to divide TEVAR and OG patients into
tertiles to reduce bias. Presented are results from the middle tertile (T2),
patients equally likely to be in TEVAR or OG and thus best matched.
Results: Correlates of TEVAR were smaller aneurysm, anticoagulants,
no previous abdominal aortic aneurysm (AAA) repair, no peripheral vascular
disease (PVD), statin use, aspirin use, older age, race, male gender, or heart
failure (all P  .05). T2 included 68 TEVAR (PS, 0.58  0.2) and 67 OG
(PS, 0.46  0.2) patients. VALOR reported differences in aneurysm size
(TEVAR, 56mm vsOG, 69mm) and prior AAA repair (19% TEVAR vs 37%
OG), and there were no differences in T2. All-cause mortality (ACM) and
aneurysm-related mortality (ARM) rates in VALOR and T2 are presented.
Age, history of cerebrovascular accident, antiarrhythmia medication, and
renal disease (all P  .05) independently predicted ACM and ARM by
regression analysis.
Conclusions: PS analysis of the VALOR trial validates both perioper-
ative and long-term benefits (ARM) conferred by TEVAR in patients
undergoing descending thoracic aneurysm repair.
Table. Mortality outcomes
Mortality




P(n  195) (n  189) (n  68) (n  67)
30-day 4 (2%) 12 (8%) .01 0 2 (3%) .05
ACM 31 (16%) 39 (21%) .17 11 (17%) 10 (15%) .8
ARM 6 (3%) 22 (12%) .01 0 5 (8%) .03
ACM,All-cause mortality;ARM, aneurysm-relatedmortality;OG, historical
surgical controls; TEVAR, thoracic endovascular aneurysm repair.
Outcome of Endovascular Abdominal Aortic Aneurysm Repair in
Octogenarians and Nonagenarians: Single-Center Experience
Stuart B. Prenner, Irene C. Turnbull,RajeshMalik,Alexander Salloum,
Sharif H. Ellozy, Angeliki G. Vouyouka, Michael L. Marin, and Peter L.
Faries, From the Mount Sinai School of Medicine, New York, NY
Objective: Compared with open repair of abdominal aortic aneurysms
(AAA), endovascular repair (EVAR) is associated with decreased periopera-
tive morbidity and mortality in a standard patient population. This study
sought to determine if the advantage of EVAR extends to patients80 years
of age.
Methods: This was a retrospective review from a prospectively main-
tained computer database. From January 1997 to November 2007, 323
patients (78.6% male) aged 80 underwent elective EVAR. Mean age was
84 3.4 years (range, 80-95 years). Mean aneurysm size was 6.2 cm (range,
2.6-11.0 cm; Table).
Results: Mean procedural blood loss was 350 mL (range, 100-2700
mL), and 16.4% required intraoperative transfusion. Mean postoperative
length of stay was 2.46 days, (median, 1 day; range, 1-42 days), with 54.3%
of patients discharged on postoperative day 1. There were 20 (6.2%)
perioperative major adverse events and a perioperative mortality rate of 3.4%
(11 of 323). Mean follow-up was 25.7 months (range, 1-110 months).
Overall, 21 patients (6.5%) required secondary intervention, 6 (1.9%) un-
derwent conversion to open repair, and 4 (1.2%) died of AAA rupture.
Freedom from all-cause mortality at 1 year was 84.3%. Freedom from
aneurysm related mortality at 5 years was 92.9% (Fig). Endoleak occurred in
95 patients (29.4%), with 20 type I, 44 type II, and 18 of indeterminate type;
of these, 10 patients with type I endoleak underwent secondary intervention.
Conclusion: Our study supports that EVAR in octogenarians is asso-
ciated with high procedural success and low perioperative morbidity and
mortality. The long-term results support the use of EVAR in this patient
population.
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Endoleak after EVAR
Christopher J. Abularrage, Robert S. Crawford, Mark F. Conrad, Christo-
pher J. Kwolek, Richard P. Cambria, and Glenn M. LaMuraglia, From
Massachusetts General Hospital, Boston, Mass
Objectives: Persistent type 2 endoleaks (PT2) present6months after
endovascular aneurysm repair (EVAR) are associated with adverse out-
comes. This study evaluated the preoperative risk factors and natural history
of PT2 to define a population at high-risk.
Methods: From 1999 to 2007, 595 of 832 (72%) EVAR patients had
long-term computed tomography (CT) follow-up and comprised the study
cohort. Preoperative anatomic and clinical variables were correlated with PT2
using Cox regression and high-risk composite variable analyses. Primary end
points included spontaneous resolution, sac enlargement5mm, and freedom
from reintervention and were evaluated using Kaplan-Meier analysis.
Results: There were 136 (23%) PT2 patients with a median follow-up
of 34.8 months (range, 6.4-121.2 years). Predictive factors included patent
inferior mesenteric artery (IMA; odds ratio [OR], 4.18; 95% confidence
interval [CI], 1.69-10.31; P .002), increasing no of patent lumbar arteries
(OR, 1.25; 95% CI, 1.10-1.42; P  .0006), increasing age (OR, 1.04; 95%
CI, 1.01-1.06; P .003), and increasing aneurysm luminal diameter shown
on CT contrast opacified lumen (OR, 1.03; 95% CI, 1.02-1.05; P .0001).
High-risk composites indicated that patients with a patent IMA and either
Table. Patient comorbidities
Comorbidity % (N  323)
Hypertension 73.7













ASA class II 1.6
ASA class III 78.9
ASA class IV 19.5
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease
Fig. Freedom from abdominal aortic aneurysm-related death.6 patent lumbar arteries, maximum luminal diameter 30 mm, or age
70 years had an approximately 10-fold increased risk of PT2 (Table).Patients with a patent IMA and any two risk factors had an approximately
20-fold risk. During follow-up, spontaneous PT2 resolution occurred in 35
patients (26%), sac diameter remained stable in 63 (46%), and rupture
occurred in 2 (1.5%). By Kaplan-Meier analysis, 35% of PT2 resolve spon-
taneously and freedom from sac enlargement 5 mm is 55% at 5 years.
Fifty-nine reinterventions were performed in 39 patients with PT2. Freedom
from reintervention was 67% at 5 years.
Conclusions: Readily identifiable preoperative variables are associated
with PT2. High-risk composites can be used to identify a cohort of patients
that should be considered for perioperative interventions to preclude PT2.
Does Renal Transplantation Improve Endovascular Interventional
Outcomes for Patients with Chronic Renal Insufficiency?
Combiz Rezayat,a Ashley Graham,a Habib Khan,a James McKinsey,a
Nicholas Morrisey,a Rajeev Dayal,a Harry Bush,b John Karwowski,b and
Roman Nowygrod,a From Columbia University Medical Centera; and
Weill Cornell Medical College,b New York, NY
Introduction: It has been suggested that preemptive renal transplan-
tation can reduce the incidence and severity of peripheral vascular disease
(PVD) and improve limb salvage. Immunosuppressed transplant patients
may have a decreased incidence of in-stent restenosis. This study compared
limb salvage and patency rates after endovascular interventions among
patients with chronic renal insufficiency (CRI), functional and failed renal
transplants (RT), and normal renal (NR) function.
Methods: A database of 1567 treated lesions from 2004 to 2009 was
cross-referenced with the RT registry for the same period (n 2283) to select
three treated patient groups: NR, 1172; CRI (creatinine 1.2 mg/dL), 349
(end-stage renal disease, 92); RT, 46 (25 functional, 21 failed). Comorbidities
and indications, and primary, secondary patencies, and limb salvage at 6, 12, 18,
24 months were assessed. P was calculated by log-rank analysis.
Results: Indications for interventions were similar for CRI and RT,
comprising claudication, 28 (39%); rest pain, 14 (4%); and tissue loss, 58
(57%). TheNR group hadmore claudicant patients (52%) and less tissue loss
(34%; P  .0001). RT patients were younger than CRI patients and had
lower rates of heart failure. NR patients had a significantly lower incidence of
diabetes than CRI and RT patients (P .002). Primary patency for NR (78%
at 6 months; 50% at 24 months) was significantly better than for CRI (P 
.019 at 6 months; P .002 at 24 months). Primary and secondary patencies
at 6 and 24 months were significantly worse for the RT group than for the
NR group (P .001). Similarly, limb salvage at 24months for RT (67%) was
significantly worse than for NR (87%, P .0001) but did not reach statistical
significance for CRI (73%, P  .058). There was a nonsignificant trend
towards improved patency results in patients with functional vs failed RT.
Conclusions: As anticipated, endovascular outcomes for patency and
limb salvage in patients with CRI were significantly worse than in patients
with NR. Restoration of renal function by transplantation does not appear to
reverse these outcomes despite the postulated beneficial effect of systemic
immunosuppression.
Repeat Angioplasty and Stenting for Femoropopliteal Occlusive
Disease: Factors Affecting Outcomes of the Second-Time Endovascular
Intervention
William P. Robinson III, Louis L. Nguyen, Richard Bafford, and Michael
Belkin, From Brigham and Women’s Hospital, Boston, Mass
Introduction: Repeat percutaneous interventions for femoropopliteal
occlusive disease are common, but the outcomes are poorly understood. We
sought to determine the results of second-time femoropopliteal percutane-
Table. High-risk composite variable analysis
Composite variable OR (95% CI)
Patent inferior mesenteric artery and
MALD 30 mm 9.15 (3.37-24.98)
6 patent LA 9.43 (3.59-24.86)
Age 70 y 9.71 (3.44-27.40)
MALD 30 mm  6 patent LA 18.49 (6.41-53.59)
MALD 30 mm  age 70 years 19.04 (6.19-8.74)
6 patent LA  age 70 years 19.62 (6.55-58.67)
MALD 30 mm  6 patent LA
 age 70 y
38.46 (11.84-125.23)
CI, Confidence interval; LA, lumbar arteries; MALD, maximum aneurysm
luminal diameter; OR, odds ratio.ous transluminal angioplasty/stenting (SPTAS) and identify factors associ-
ated with outcome.
